Hipotermia terapeutyczna — potężne narzędzie w zapobieganiu uszkodzeniu niedokrwienno-reperfuzyjnemu w sercach szczurów by Wojciechowska, Małgorzata et al.
  
ONLINE FIRST
This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.
ISSN: 2353-7752
e-ISSN: 2353-7760
Therapeutic hypothermia — a powerful tool in preventing
ischemia-reperfusion-injury in rat hearts
Authors:  Małgorzata Joanna Wojciechowska, Magdalena Kleszczewska, Anita
Trojanowska, Tomasz Ciesielski, Sonia Borodzicz-Jażdżyk, Katarzyna Czarzasta,
Liana Puchalska, Maciej Zarębiński, Agnieszka Cudnoch-Jędrzejewska
DOI: 10.5603/FC.a2021.0032




This article has been peer reviewed and published immediately upon acceptance.
It is an open access article, which means that it can be downloaded, printed, and distributed freely,
provided the work is properly cited. 
Powered by TCPDF (www.tcpdf.org)
Therapeutic hypothermia — a powerful tool in preventing ischemia-reperfusion-injury 
in rat hearts 
Hipotermia terapeutyczna — potężne narzędzie w zapobieganiu uszkodzeniu niedokrwienno-
reperfuzyjnemu w sercach szczurów 
 
Małgorzata Wojciechowska1, 2, Magdalena Kleszczewska1, Anita Trojanowska1, Tomasz 
Ciesielski1, Sonia Borodzicz-Jażdżyk1, Katarzyna Czarzasta1, Liana Puchalska1, Maciej 
Zarębiński2, Agnieszka Cudnoch-Jędrzejewska1 
1Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical 
Research, Medical University of Warsaw, Warsaw, Poland 
2Independent Public Specialist Western Hospital John Paul II, Invasive Cardiology Unit, 
Grodzisk Mazowiecki, Poland 
 
 
Address for correspondence: Małgorzata Wojciechowska MD, Zakład Fizjologii 
Doświadczalnej i Klinicznej, Laboratorium Centrum Badań Przedklinicznych, Warszawski 
Uniwersytet Medyczny, ul. Banacha 1B, 02–097 Warszawa, phone +48 22 116 6113, fax +48 




Introduction. The aim of the experiment was to find the relationship between the extent of 
myocardial infarction and the internal body temperature of the rats. Our second goal was to 
investigate if mild hypothermia applied during myocardial ischemia and reperfusion brings 
cardioprotective effects. 
Materials and methods. The study was performed in vivo on rat hearts. Myocardial 
infarction was induced by 30 minutes of the left anterior descending artery occlusion followed 
by 60 min reperfusion. Thirteen rats were assigned to a group depending on the internal body 
temperature (t) ≤ 35.5°C (n = 5), 35.6 ≥ t ≥ 37.5°C (n = 4) and t ≥ 37.6°C (n = 4). The desired 
temperature was achieved during pre-ischemic procedures. The presence of the infarction scar 
and its size were assessed in planimetry. Infraction size was calculated as the infarct area 
relative to the area at risk (IA/RA). 
Results. The incidence of infarction scar in the groups of rats with body temperature ≥ 35.6°C 
was significantly higher (p < 0.01) compared to the group with the temperature ≤ 35.5°C. 
There was statistically significant positive correlation (r = 0.787, p < 0.01) between IA/RA 
and the internal body temperature of the rats. 
Conclusions. Any reduction in the body temperature during myocardial ischemia and 
reperfusion seems to be beneficial for the rat’s myocardium. Moreover, hypothermia ≤ 35.5ºC 
applied during ischemia and reperfusion fully prevents from myocardial infarction. We 
believe that there is a great need to intensify research on therapeutic hypothermia in humans, 
so that this method of treatment could be finally used in the course of myocardial infarction. 





Percutaneous coronary intervention is a treatment of choice in patients with ST-elevation 
myocardial infraction (STEMI). Unfortunately, the reperfusion itself leads to further 
myocardial damage and the final area of infarction is the result of ischemia and reperfusion 
injury (IRI). Many methods for diminishing IRI have been tested; one of them is therapeutic 
hypothermia (TH) [1]. TH is widely used for myocardial protection during cardiac surgery 
and also for neurological protection after sudden cardiac arrest, but still not established in the 
course of myocardial infarction (MI). 
The aim of this study was to investigate the influence of internal body temperature of 
the rats during myocardial ischemia and reperfusion on the infarct size. Our second goal was 
to determine if mild hypothermia applied during myocardial ischemia and reperfusion is 
cardioprotective. In the article we also present data from clinical trials and shortly discuss the 
discrepancy in effectiveness of TH between experimental studies and clinical trials. 
 
Materials and methods 
 
The study was performed in 13 female Sprague Dawley rats. All the experiments were 
conducted in compliance with National Research Council‘s guidelines for the care and use of 
laboratory animals. All procedures were also approved by the Local Ethical Committee. 
Animals were anaesthetized by intraperitoneal administration of ketamine (100 mg/kg) and 




Rats were connected to a rodent ventilator (Harvard Apparatus — VentElite) and ventilated 
with room air at the breathing rate of 100/min and the tidal volume of 1 mL/100 g body mass. 
The electrocardiographic monitoring was performed continuously (limb leads). In each 
animal, the chest was opened through the fifth intercostal space. Left anterior descending 
artery (LAD) was ligated at the bottom of the left atrium. Ischemia was confirmed by 




A          B 
    
Figure 1. ST-elevation after left anterior descending (LAD) occlusion: A. Sinus bradycardia 
75/min in rat with internal temperature 35.1°C; B. Normal sinus rhythm 170/min with single 
ventricular extra beat in rat with internal body temperature 38.0°C 
 
 
Detection of the myocardial infarction 
After 60 min of reperfusion, the LAD was occluded again and 2 ml of 5% Evans Blue was 
administered intravenously. All perfused tissues tinted dark blue and the myocardium 
supplied by the occluded artery remained pink [area at risk (RA)]. The assessment of the 
infarct area (IA) was made by tetrazolium staining with the use of planimetric method 
(ImageJ) [2]. 
To measure IA independently from anatomical variability of vascularization, IA as a 
percentage of RA was calculated. 
 
Temperature monitoring and perioperative hypothermia 
Our goal was to achieve the internal body temperatures from 35.0 to 38.5°C. After anesthesia 
and shaving, the animals were put on an operating table, which was covered with a 
temperature controlled heating pad. The temperature of the heating pad was regulated and the 
desired internal body temperature was achieved before the start of ischemia. The temperature 
was recorded by a rodent rectal thermometer and from the beginning of ischemia to the end of 
reperfusion it was kept close to the intended target. 
 
Statistical analysis 
The animals were assigned to a group depending on the internal body temperature (t) ≤ 
35.5°C (n = 5), 35.6 ≥ t ≥ 37.5°C (n = 4) and t ≥ 37.6°C (n = 4). Differences in the incidence 
of infarction scar between the groups (assessed by the presence of IA or not), were tested with 
the Chi-square test. 
The Spearman correlation was used to test the correlation between the body 
temperature of the rats and the infarct area relative to the area at risk (IA/RA). Due to the lack 
of infarcts in the animals with the temperature ≤ 35.5°C, the mean value of the temperature in 




The internal body temperatures of the rats ranged from 34.8 to 38.6°C (Table 1). In the groups 
of rats with body temperature 35.6 ≥ t ≥ 37.5°C (n = 4) and ≥ 37.6°C (n = 4) in all animals IA 
was clearly visible (Figure 2A, B). In the group with body temperature ≤ 35.5°C (n = 5), IA 
has not been detected at all in any of the rats (Figure 2C). The frequency of IA detected in 
planimetry in groups of rats with body temperature ≥ 35.6°C was significantly higher (p < 
0.01) compared to the group with the temperature ≤ 35,5ºC (Table 2). There was statistically 
significant positive correlation (r = 0.787; p < 0.01) between IA/RA and the body temperature 
of the rats (Figure 3). 
 
 
Table 1. Internal body temperatures of the rats (n = 13) and the corresponding infarct area 
relative to the area at risk (IA/RA) ratios 
Internal body temperature 














Figure 2. Transverse cross-sections of the hearts (examples). White color — infarct area (IA), 
red— myocardium at risk (RA), blue— area not supplied by left anterior descending: A. 
Temperature 38.0°C, clearly visible IA; B. Temperature 36.0°C, small IA in subendocardium; 
C. Temperature 35.1°C, no visible IA 
 
 
Table 2. The incidence of infarction scar depending on internal body temperature (Chi2 
Pearson: 13.00, df = 2, p < 0.01) 
Temperature range [°C] Presence of infarction scar 
(IA, infarct area) 
Yes No 
t ≤ 35.5 0 5 (100%) 
35.6 ≤ t ≤ 37.5 4 (100%) 0 




Figure 3. Correlation between infarct area relative to the area at risk (IA/RA) and the internal 




TH in experimental studies 
Cardioprotective effects of TH have been demonstrated in different animal models of IRI [3–
7]; however, only few of them have been performed on rats [5, 7]. Due to little coronary 
collateral circulation, reliable infarct production and relatively high survival rate, rats have 
become commonly used models in translational research for IRI experiments [8]. 
The aim of our study was to investigate the dependence of the infarct size on internal 
temperature of the animals during ischemia and reperfusion. As the applied hypothermia 
varies between the experiments in a range of 32–36ºC [3–7] our second goal was to determine 
if mild hypothermia brings cardioprotective effects. 
The most important finding of our experiment is that in the course MI induced by 30 
min of ischemia and 60 min of reperfusion, the internal body temperature in the range of 
34.8–38.6ºC is positively correlated with the IA/RA ratio. Interestingly, this relationship is 
also visible within the normal range (37.5–38.5ºC), which means that any reduction in body 
temperature during ischemia and reperfusion is beneficial for the myocardium [9]. On the 
other hand, it also means that inadequate temperature control may be a source of noise in 
infarct size studies [2]. 
In the group of rats with body temperature ≤ 35.5ºC infarction has not been detected at 
all and it can be generally deduced, that the temperature point, below which cardioprotective 
effects of hypothermia become evidently visible is 35.5ºC. As hypothermia depresses all 
physiological functions, including cardiac (e.g. through bradycardia), it seems that energy 
demands of the cardiomyocytes ≤ 35.5ºC are so reduced, that 30 min of ischemia is too short 
to lead to cell death. 
Our results indicate that mild hypothermia is cardioprotective [4, 6] and there is no 
need to lower the temperature to 32–34ºC. Similar results were obtained with the 
neuroprotection [10]. It seems important, since the higher the target temperature, the easier it 
is to reach it; moreover, the risk of possible complications decreases. 
 
TH in clinical trials 
The results of clinical trials on TH and MI are inconclusive [11]. A small analysis carried out 
in humans demonstrated that the area of infraction in comparison with the myocardium at risk 
after TH was significantly reduced [12]. On the other hand, CHILL-MI trial, which was 
performed on 120 patients with STEMI, demonstrated that TH did not significantly reduce the 
area of MI [13]. Another multi-center randomized trial on 101 patients showed that the TH 
had no impact on myocardial salvage assessed in magnetic resonance [14]. However, 
systemic review and meta-analyses [15, 16], same as detailed analysis of negative studies 
mentioned above: CHILL-MI trial and the study of Testori et al. [13, 14] showed that patients 
with STEMI of anterior wall was the subgroup that significantly benefited from TH. Also a 
study of Noc et al. [17] showed absolute 30% reduction of infarct size in anterior STEMI 
patients. 
 
Failure to transfer TH from animal models to the clinic 
Despite the very good results obtained in animals, the results in humans are not so 
spectacular. Too late implementation of TH may be the reason, as in most clinical studies 
hypothermia was induced only before reperfusion therapy [13, 15, 17], which in some cases 
additionally delayed invasive treatment. In contrast, in most animal studies TH was applied at 
the beginning of ischemia [3, 6, 7]. In one of the study performed on rabbits it was shown that 
the later TH was induced during the ischemia-reperfusion period, the worse the benefits were; 
however, the temperature at the time of reperfusion most strongly correlated with the degree 
of IRI [4]. Therefore, we believe that one of the methods to improve the benefits of TH in 
clinical trials is to initiate TH before hospital, preferably at the time of first medical contact. 
Conventional method of inducing TH, which is cold saline infusion or surface cooling 
systems like cooling blankets or pads, can be easily used. And it is not about pre-hospital 
achieving the desired temperature, but any reduction of the temperature seems to be beneficial 
and speeds up getting the target with more advanced method. 
Another aspect that may be important is the type of MI. In animal studies MI is 
usually induced by the LAD occlusion [5–8], which in electrocardiography causes ST 
segment elevation. This may suggest that clinical trials should focus on patients with STEMI 
of anterior wall, which is partly evidenced by the encouraging effects of hypothermia in this 
group, which was discussed above. 
There are many other questions concerning TH in humans, like the best cooling 
method (intravascular? intracoronary?), the desired temperature, the duration of hypothermia 
during reperfusion and heating rate. All of these are important and necessary to establish. 
 
Limitations of the study 
 
Some consider the 60 min of reperfusion is too short for tetrazolium staining. However, based 
on our previous experience and other studies [18–20], this reperfusion was long enough for 
the relevant areas to be easily outlined. 
Also the method of induction and maintenance of hypothermia may be a limitation of 






Hypothermia ≤ 35.5ºC applied during 30 min of ischemia and 60 min reperfusion is a 
powerful tool to decrease the infarction area. Moreover, any reduction in body temperature 
during ischemia and reperfusion, also within the normal range, is beneficial for the rat’s 
myocardium. We conclude that further research on hypothermia is necessary to transfer this 
powerful tool into clinical practice, so that TH could be used in the course of MI in humans. 
 





Wstęp. Celem doświadczenia było zbadanie zależności obszaru zawału (IA) od temperatury 
wewnętrznej szczurów oraz określenie, czy łagodna hipotermia zastosowana podczas 
niedokrwienia i reperfuzji działa kardioprotekcyjne. 
Materiały i metody. Badanie przeprowadzono in vivo na sercach szczurzych. Zawał serca 
wywoływano poprzez 30-minutowe zamknięcie gałęzi przedniej zstępującej (LAD), po czym 
następowała 60-minutowa reperfuzja. Trzynaście szczurów przydzielono do grup zależnie od 
wewnętrznej temperatury ciała (t) ≤ 35,5°C (n = 5), 35,6 ≥ t ≥ 37,5°C (n = 4) oraz t ≥ 37,6°C 
(n = 4). Pożądaną temperaturę wewnętrzną osiągano podczas czynności poprzedzających 
rozpoczęcie niedokrwienia. Obecność zawału i jego rozmiar oceniano planimetrycznie. 
Obszar blizny zawałowej określano jako procent obszaru zagrożonego martwicą (RA). 
Wyniki. Występowanie blizny zawałowej w ocenie planimetrycznej w grupach zwierząt z 
temperaturą ≥ 35,6°C było znacząco wyższe (p < 0,01) niż w grupie z temperaturą ≤ 35,5ºC. 
Wykazano istotną statystycznie pozytywną korelację (r = 0,787; p < 0,01) między IA/RA a 
wewnętrzną temperaturą ciała szczurów. 
Wnioski. Nawet niewielkie obniżenie temperatury ciała podczas niedokrwienia i reperfuzji 
wydaje się korzystne dla zmniejszenia uszkodzenia miokardium. Co więcej, zastosowanie 
hipotermii ≤ 35,5ºC podczas niedokrwienia i reperfuzji pozwala w pełni zapobiec wystąpieniu 
obszaru martwicy w sercach szczurzych. Autorzy niniejszej pracy wierzą, że istnieje duża 
potrzeba poszerzenia badań na temat hipotermii, tak aby metoda ta mogła ostatecznie znaleźć 
zastosowanie u chorych z ostrym zespołem wieńcowym. 
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